Coenzyme Q10 Absorption and Tolerance in Children With Down Syndrome: A Dose-Ranging Trial

Pediatric Neurology

Volumn 35, Issue 1, 2006, Pages 30-37

  Miles, Michael V ^a   Patterson, Bonnie J ^b   Schapiro, Mark B ^a   Hickey, Francis J ^b   Chalfonte Evans, Melinda ^b   Horn, Paul S ^c   Hotze, Stephanie L ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UBIDECARENONE; DRUG DERIVATIVE; UBIQUINONE;

ADOLESCENT; APPETITE DISORDER; ARTICLE; BEHAVIOR; BEHAVIOR DISORDER; BLOOD CELL COUNT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOWN SYNDROME; DRUG ABSORPTION; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; HYPERACTIVITY; LABORATORY TEST; LOW DRUG DOSE; MALE; PARENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; TREATMENT WITHDRAWAL; ABSORPTION; BLOOD; CHEMICALLY INDUCED DISORDER; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; INFANT; PHYSIOLOGY; PRESCHOOL CHILD;

ABSORPTION; BEHAVIORAL SYMPTOMS; CHEMISTRY, PHARMACEUTICAL; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN SYNDROME; FEMALE; HUMANS; INFANT; MALE; UBIQUINONE;

EID: 33745249920     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2005.11.004     Document Type: Article

References (42)

1. de Haan J.B., Susil B., Pritchard M., and Kola I. An altered antioxidant balance occurs in Down syndrome fetal organs. Implications for the "gene dosage effect" hypothesis. J Neural Transm 67 Suppl. (2003) 67-83
2. Muchova J., Sustrova M., Garaiova I., et al. Influence of age on activities of antioxidant enzymes and lipid peroxidation products in erythrocytes and neutrophils of Down syndrome patients. Free Radic Biol Med 31 (2001) 499-508
3. Carratelli M., Porcaro L., Ruscica M., De Simone E., Bertelli A.A., and Corsi M.M. Reactive oxygen metabolites and prooxidant status in children with Down's syndrome. Int J Clin Pharmacol Res 21 (2001) 79-84
4. Capone G., Kim P., Jovanovich S., et al. Evidence for increased mitochondrial superoxide production in Down syndrome. Life Sci 70 (2002) 2885-2895
5. Sinha S. Anti-oxidant gene expression imbalance, aging and Down syndrome. Life Sci 76 (2005) 1407-1426
6. Kim S.H., Vlkolinsky R., Cairns N., Fountoulakis M., and Lubec G. The reduction of NADH ubiquinone oxidoreductase 24- and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer's disease. Life Sci 68 (2001) 2741-2750
7. Thiel R., and Fowkes S.W. Can cognitive deterioration associated with Down syndrome be reduced?. Med Hypotheses 64 (2005) 524-532
8. Cammer W. Protection of cultured oligodendrocytes against tumor necrosis factor-alpha by the antioxidants coenzyme Q(10) and N-acetyl cysteine. Brain Res Bull 58 (2002) 587-592
9. 10 in patients with a load-induced cardiac dysfunction. Mol Aspects Med 18 Suppl. (1997) s153-s158
10. 10 confers cardiovascular protection against acute mevinphos intoxication by ameliorating bioenergetic failure and hypoxia in the rostral ventrolateral medulla of the rat. Shock 23 (2005) 353-359
11. 10 deficiency. Neurology 56 (2001) 849-855
12. Lodi R., Hart P.E., Rajagopalan B., et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann Neurol 49 (2001) 590-596
13. 10 and remacemide in Huntington's disease. Neurology 57 (2001) 397-404
14. 10 in early Parkinson disease. Evidence of slowing of the functional decline. Arch Neurol 59 (2002) 1541-1550
15. 10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett 341 (2003) 201-204
16. 10 deficiency. Neurology 60 (2003) 1206-1208
17. Hart P.E., Lodi R., Rajagopalan B., et al. Antioxidant treatment of patients with Friedreich ataxia. Four-year follow-up. Arch Neurol 62 (2005) 621-626
18. 10 in patients with end-stage heart failure awaiting cardiac transplantation. A randomized, placebo-controlled study. Clin Cardiol 27 (2004) 295-299
19. 10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. J Thorac Cardiovasc Surg 129 (2005) 25-32
20. Kuettner A., Pieper A., Koch J., Enzmann F., and Schroeder S. Influence of coenzyme Q(10) and cerivastatin on the flow-mediated vasodilation of the brachial artery. Results of the ENDOTACT study. Int J Cardiol 98 (2005) 413-419
21. 10 improves blood pressure and glycaemic control. A controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 56 (2002) 1137-1142
22. Watts G.F., Playford D.A., Croft K.D., Ward N.C., Mori T.A., and Burke V. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia 45 (2002) 420-426
23. 10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis 168 (2003) 169-179
24. 10 in isolated systolic hypertension. South Med J 94 (2001) 1112-1117
25. Cicero A.F., Derosa G., Miconi A., Laghi L., Nascetti S., and Gaddi A. Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates. Biomed Pharmacother 59 (2005) 312-317
26. Finsterer J. Mitochondriopathies. Eur J Neurol 11 (2004) 163-186
27. Scarlato G., Bresolin N., Moroni I., et al. Multicenter trial with ubidecarenone. Treatment of 44 patients with mitochondrial myopathies. Rev Neurol (Paris) 147 (1991) 542-548
28. 10 improves mitochondrial respiration in patients with mitochondrial cytopathies. Cell Mol Biol (Noisy-le-grand) 43 (1997) 741-749
29. 10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation. Diabetologia 41 (1998) 584-588
30. 10 deficiency. Lancet 356 (2000) 391-395
31. 10 deficiency. Neurology 57 (2001) 515-518
32. 10 therapy in mitochondrial ophthalmoplegia. Eur J Med Res 8 (2003) 485-491
33. Marriage B.J., Clandinin M.T., Macdonald I.M., and Glerum D.M. Cofactor treatment improves ATP synthetic capacity in patients with oxidative phosphorylation disorders. Mol Genet Metab 81 (2004) 263-272
34. 10 in patients with Parkinson's disease. Exp Neurol 188 (2004) 491-494
35. 10 in man. Int J Clin Pharmacol Ther Toxicol 24 (1986) 536-541
36. 10 formulations in human subjects. Int J Vitam Nutr Res 68 (1998) 109-113
37. 10 in human plasma. Clin Chem 47 (2001) 256-265
38. 10 concentrations and redox state in apparently healthy children and adults. Clin Chim Acta 347 (2004) 139-144
39. David O., Fiorucci G.C., Tosi M.T., et al. Hematological studies in children with Down syndrome. Pediatr Hematol Oncol 13 (1996) 271-275
40. 10 use in neurologic and muscular diseases. Am J Clin Pathol 121 Suppl. (2004) S113-S120
41. 10 in the treatment of idiopathic dilated cardiomyopathy in children. Int J Cardiol 88 (2003) 101-102
42. ® Monograph (website www.cancer.gov/cancertopics/pdq/cam/coenzymeQ10/healthprofessional). National Cancer Institute. January 11, 2005.